FreeNo sign-upNo subscriptionNo affiliate links
Free tesamorelin reconstitution calculator. Enter vial size (2-5 mg), BAC water volume, and dose to get concentration, syringe units, and doses per vial. Includes the FDA-approved 2 mg daily protocol, visceral fat reduction dosing, and GHRH comparison. Verify tesamorelin quality with independent lab test data on Peptigrity.
A 5 mg vial of tesamorelin reconstituted with 1 mL of bacteriostatic water gives a concentration of 5.0 mg/mL, or 50 mcg per unit on a U-100 syringe. For a 2 mg dose, draw the syringe to 40.0 units (0.40 mL). At that dose the vial provides about 2.5 doses.
Defaults: 5 mg vial + 1 mL from this page's reconstitution quick reference; 2 mg is the "Standard (FDA)" row of this page's dose ladder, used here for arithmetic only. The calculator keeps that 1 mL while your dose lands on a line of your syringe — or set your own.
How many mg is on the label?
Bacteriostatic water — not sure how much? Let the calculator pick.
How much per shot?
2 mg = 2,000 mcg
Pick the one in your hand.
Not sure? Look at the biggest number printed on the barrel — 30, 50 or 100.
Check the box says U-100. Syringes for pet insulin (U-40) look the same but their lines measure 2.5× more liquid. This calculator is for U-100 syringes only.
Each line on this syringe = 2 units = 100 mcg.
Easy check: 10 units = 500 mcg · 20 units = 1 mg
| Step | Dose | Draw on a 1 mL syringe | Doses per vial |
|---|---|---|---|
| Low dose | 1 mg | 20 units | 5 |
| Standard (FDA) | 2 mg | 40 units | 2 |
Tap any row to load that dose into the calculator above.
Log it week by week in the free peptide tracker and check your vial's lot against lab tests on file. Private until you publish.
Tesamorelin is a 44-amino-acid GHRH analogue - the only FDA-approved peptide in this calculator suite (marketed as Egrifta SV for HIV-associated lipodystrophy). The approved dose is 2 mg subcutaneously once daily. Community protocols vary from this anchor.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| FDA-approved | 2 mg (2,000 mcg) | 1× daily | Ongoing (clinical trials: 26-52 weeks) | Established in Phase 3; subcutaneous abdomen |
| Standard community | 1-2 mg | 1× daily | 8-12 weeks on / 4 weeks off | Cycling to manage GH receptor sensitivity |
| 5-on-2-off | 2 mg | 5 days on / 2 off | 12 weeks | Reduces weekly consumption by ~29% |
| Tesa + Ipa stack | 1-2 mg tesa + 200-300 mcg ipa | 1× daily (evening) | 8-12 weeks | GHRH + GHRP synergy; see blend calculator |
| Vial | BAC Water | Conc. | 1 mg Draw | 2 mg Draw | Doses (2 mg) |
|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 20 units | 40 units | 2.5 |
| 5 mg | 2.5 mL | 2 mg/mL | 50 units | 100 units (full) | 2.5 |
| 10 mg | 2 mL | 5 mg/mL | 20 units | 40 units | 5 |
| 10 mg | 5 mL | 2 mg/mL | 50 units | 100 units (full) | 5 |
Common: 5 mg vial + 1 mL BAC water = 5 mg/mL. The FDA 2 mg dose = 40 units - a clean, manageable draw. At 2 mg/mL (2.5 mL BAC), the same dose fills the entire syringe. For technique, see reconstituting peptides step by step.
| Vial | 1 mg / day | 2 mg / day | 2 mg 5-on-2-off |
|---|---|---|---|
| 5 mg | 5 days | 2.5 days | ~3.5 days |
| 10 mg | 10 days | 5 days | ~7 days |
Tesamorelin is consumed rapidly - a 30-day cycle at 2 mg daily requires 12 × 5 mg vials or 6 × 10 mg vials. The 5-on-2-off protocol reduces this to approximately 9 × 5 mg vials per month.
| Property | Tesamorelin | Sermorelin | CJC-1295 (no DAC) |
|---|---|---|---|
| Full name | Modified GHRH(1-44) | GHRH(1-29) | Modified GHRH(1-29) + 4 AA changes |
| Amino acids | 44 | 29 | 29 (modified) |
| FDA status | Approved (Egrifta SV) | NDA withdrawn (2008) | Not approved |
| Modification | Trans-3-hexenoic acid at N-terminal | None (truncated native) | 4 amino acid substitutions for DPP-IV resistance |
| Half-life | ~26 min (longer effective due to modification) | ~10-20 min | ~30 min |
| Typical dose | 2 mg daily | 200-500 mcg daily | 100-300 mcg 1-2× daily |
| Clinical data | Phase 3 trials (n=800+) | Limited clinical | Minimal clinical |
| WADA status | Prohibited (S2) | Prohibited (S2) | Prohibited (S2) |
The tesamorelin + ipamorelin combination pairs a GHRH analogue with a selective GHRP. Tesamorelin provides the releasing hormone signal while ipamorelin triggers GH release through the ghrelin receptor - without elevating cortisol or prolactin. This combination is available as pre-made blend vials from several peptide vendors. For blend dosing, use the Blend Calculator with the Tesa + Ipa preset.
Tesamorelin is a 44-amino-acid peptide with MW of approximately 5,135.9 Da. Check the CoA for ≥98% HPLC purity and mass spectrometry confirming MW. The trans-3-hexenoic acid modification at the N-terminal should be verifiable. Cross-reference with independent lab test results. For CoA interpretation, see red flags in peptide CoAs.
At 5 mg/mL (5 mg + 1 mL BAC water): 2 mg = 40 units. At 2 mg/mL (5 mg + 2.5 mL): 2 mg = 100 units (a full syringe). Use 1 mL BAC water for cleaner draws.
The FDA-approved dose is 2 mg subcutaneously once daily, based on Phase 3 trials for HIV-associated lipodystrophy. This is the only FDA-approved peptide in the Peptigrity tool suite.
Both are GHRH analogues. Tesamorelin is FDA-approved (44 amino acids, trans-3-hexenoic acid modification) with robust clinical data. Sermorelin is shortened GHRH(1-29) with its NDA withdrawn. Tesamorelin has a longer effective half-life.
Yes - the Tesa + Ipa stack is one of the most popular GHRH + GHRP combinations. Use the Blend Calculator for combined vial dosing.
At 2 mg daily: 12 × 5 mg vials or 6 × 10 mg vials per 30 days. The 5-on-2-off protocol reduces this to ~9 × 5 mg vials.
Yes. Tesamorelin is on the WADA Prohibited List (S2) as a GH-releasing factor, prohibited in- and out-of-competition.
A 5 mg vial at 2 mg/day lasts about 2.5 days. A 10 mg vial lasts 5 days. Tesamorelin is one of the fastest-consumed peptides - plan supply accordingly.